Palbociclib - Revision history

Michal Harel at 08:54, 21 January 2024

Michal Harel — Sun, 21 Jan 2024 08:54:03 GMT

←Older revision		Revision as of 08:54, 21 January 2024
Line 1:		Line 1:
-	<StructureSection load='' size='340' side='right' caption='~~Caption for this structure~~' scene='10/1001138/Cv/1'>	+	<StructureSection load='' size='340' side='right' caption='Palbociclib' scene='10/1001138/Cv/1'>
	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref>		Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref>

Alexander Berchansky at 12:20, 12 October 2023

Alexander Berchansky — Thu, 12 Oct 2023 12:20:43 GMT

←Older revision		Revision as of 12:20, 12 October 2023
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'>
-	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> ~~See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].~~	+	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref>

	In the G1 phase of the cell cycle, mammalian cells must pass a checkpoint, known as the restriction point "R", in order to complete the cell cycle and divide. CDK4 and CDK6 complex with cyclin D drive the phosphorylation of the retinoblastoma protein, Rb, which allows the cell to pass R and commit to division. Regulation of one or more proteins involved in this checkpoint is lost in many cancers. However, by inhibiting CDK4/6, palbociclib ensures that the cyclin D-CDK4/6 complex cannot aid in phosphorylating Rb. This prevents the cell from passing R and exiting G1, and in turn from proceeding through the cell cycle.<ref name="a5">PMID:28438180</ref>		In the G1 phase of the cell cycle, mammalian cells must pass a checkpoint, known as the restriction point "R", in order to complete the cell cycle and divide. CDK4 and CDK6 complex with cyclin D drive the phosphorylation of the retinoblastoma protein, Rb, which allows the cell to pass R and commit to division. Regulation of one or more proteins involved in this checkpoint is lost in many cancers. However, by inhibiting CDK4/6, palbociclib ensures that the cyclin D-CDK4/6 complex cannot aid in phosphorylating Rb. This prevents the cell from passing R and exiting G1, and in turn from proceeding through the cell cycle.<ref name="a5">PMID:28438180</ref>

Alexander Berchansky at 12:19, 12 October 2023

Alexander Berchansky — Thu, 12 Oct 2023 12:19:55 GMT

←Older revision		Revision as of 12:19, 12 October 2023
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'>
	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].		Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].
		+
		+	In the G1 phase of the cell cycle, mammalian cells must pass a checkpoint, known as the restriction point "R", in order to complete the cell cycle and divide. CDK4 and CDK6 complex with cyclin D drive the phosphorylation of the retinoblastoma protein, Rb, which allows the cell to pass R and commit to division. Regulation of one or more proteins involved in this checkpoint is lost in many cancers. However, by inhibiting CDK4/6, palbociclib ensures that the cyclin D-CDK4/6 complex cannot aid in phosphorylating Rb. This prevents the cell from passing R and exiting G1, and in turn from proceeding through the cell cycle.<ref name="a5">PMID:28438180</ref>

	<scene name='10/1001138/Overall/3'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).		<scene name='10/1001138/Overall/3'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).

Alexander Berchansky at 10:48, 11 October 2023

Alexander Berchansky — Wed, 11 Oct 2023 10:48:38 GMT

←Older revision		Revision as of 10:48, 11 October 2023
Line 2:		Line 2:
	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].		Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].

-	<scene name='10/1001138/Overall/1'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).	+	<scene name='10/1001138/Overall/3'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).

	<scene name='10/1001138/Binding_site/1'>Palbociclib binding site</scene>.		<scene name='10/1001138/Binding_site/1'>Palbociclib binding site</scene>.

Alexander Berchansky at 10:46, 11 October 2023

Alexander Berchansky — Wed, 11 Oct 2023 10:46:49 GMT

←Older revision		Revision as of 10:46, 11 October 2023
Line 3:		Line 3:

	<scene name='10/1001138/Overall/1'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).		<scene name='10/1001138/Overall/1'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).
		+
		+	<scene name='10/1001138/Binding_site/1'>Palbociclib binding site</scene>.

	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>

Alexander Berchansky at 10:34, 11 October 2023

Alexander Berchansky — Wed, 11 Oct 2023 10:34:55 GMT

←Older revision		Revision as of 10:34, 11 October 2023
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'>
-	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]). <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].	+	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].
		+
		+	<scene name='10/1001138/Overall/1'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).

	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>

Alexander Berchansky at 10:26, 11 October 2023

Alexander Berchansky — Wed, 11 Oct 2023 10:26:33 GMT

←Older revision		Revision as of 10:26, 11 October 2023
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'>
-	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].	+	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]). <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].

	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>

Alexander Berchansky at 10:24, 11 October 2023

Alexander Berchansky — Wed, 11 Oct 2023 10:24:16 GMT

←Older revision		Revision as of 10:24, 11 October 2023
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'>
-	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].	+	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].

	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>

Alexander Berchansky at 10:22, 11 October 2023

Alexander Berchansky — Wed, 11 Oct 2023 10:22:07 GMT

←Older revision		Revision as of 10:22, 11 October 2023
Line 1:		Line 1:
-	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''>	+	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'>
	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].		Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].

Alexander Berchansky at 10:18, 11 October 2023

Alexander Berchansky — Wed, 11 Oct 2023 10:18:40 GMT

←Older revision		Revision as of 10:18, 11 October 2023
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''>
-	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].	+	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].

	</StructureSection>		</StructureSection>
	== References ==		== References ==
	<references/>		<references/>